GILEAD SCIENCES, INC. - 08 Aug 2025 Form 4 Insider Report for ASSEMBLY BIOSCIENCES, INC. (ASMB)

Reporting relationship: 10%+ Owner
Issuer ticker: ASMB
Reported as of: 08 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Oct 2025, 16:30:21 UTC
Prior SEC filing: 06 Jun 2025
Next SEC filing: 01 Dec 2025
Source filing: View source filing
Reporting owner signature: Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson

Key filing fact

GILEAD SCIENCES, INC. filed Form 4 for ASSEMBLY BIOSCIENCES, INC. (ASMB) on 03 Oct 2025.

Key facts

This page summarizes GILEAD SCIENCES, INC.'s Form 4 filing for ASSEMBLY BIOSCIENCES, INC. (ASMB).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Oct 2025, 16:30.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000882095 Primary reporting owner

GILEAD SCIENCES, INC.

Relationship: 10%+ Owner
Address: 333 LAKESIDE DRIVE, FOSTER CITY
Signature: Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
Signature date: 03 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ASMB transaction

Common Stock

Purchase

Transaction value
Shares: +2,295,920
Change %: +104%
Price
Shares after: 4,505,391
Date: 08 Aug 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ASMB transaction Derivative

Class A warrants to purchase Common Stock

Purchase

Transaction value
Shares: +1,147,960
Change %
Price
Shares after: 1,147,960
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,147,960
Exercise price: $21.60
Footnotes: F1, F2

ASMB transaction Derivative

Class B warrants to purchase Common Stock

Purchase

Transaction value
Shares: +1,147,960
Change %
Price
Shares after: 1,147,960
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,147,960
Exercise price: $21.60
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 2,295,920 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), Class A warrants to purchase 1,147,960 shares of Common Stock (the "Class A Warrants"), and Class B warrants to purchase 1,147,960 shares of Common Stock (the "Class B Warrants"), at a combined price of $19.60 per share of Common Stock and accompanying one half of one Class A Warrant and one half of one Class B Warrant.

Footnote F2

The Class A Warrants are exercisable at any time after the date of issuance and expire on the earlier of (i) five years from the date of issuance, or August 11, 2030, and (ii) the date that is 30 days after the public announcement that the Issuer has completed enrollment (of at least 200 patients total) for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir. A holder of the Class A Warrants may not exercise the Class A Warrants if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

Footnote F3

The Class B Warrants are exercisable at any time after November 15, 2026 and expire on December 31, 2026, provided that the Class B Warrants will automatically terminate in full and be extinguished and will no longer be exercisable in the event that the Issuer publicly announces prior to November 15, 2026 that the Issuer has received at least $75 million in the aggregate of non-dilutive capital in connection with a collaboration agreement. A holder of the Class B Warrants may not exercise the Class B Warrants if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.